Ara
Toplam kayıt 35, listelenen: 31-35
Deciphering the implications of MAFLD and MASLD definitions in the NAFLD population: Results from a single-center biopsy study
(Wolters Kluwer Medknow Publications, 2024)
To the Editor: The nomenclature for steatotic liver disease has been a topic of debate since 2020. The conventional expression, non-alcoholic fatty liver disease (NAFLD), was introduced in 1980 to describe the occurrence ...
A phase 3 trial of seladelpar in primary biliary cholangitis
(Massachussetts Medical Society, 2024)
Effective treatments for patients with primary biliary cholangitis are limited. Seladelpar, a peroxisome proliferator–activated receptor delta agonist, has potential benefits. METHODS In this phase 3, 12-month, double-blind, ...
Prevalence, determinants, and fibrosis risk stratification of metabolic-associated fatty liver disease in a Turkish primary care setting: A retrospective study
(Kare Publishing, 2023)
Background and Aim: Metabolic-associated fatty liver disease (MAFLD) is a condition that frequently goes unnoticed as it typically remains asymptomatic until progressing to an advanced stage. As a result, it is essential ...
Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis
(Wiley, 2024)
Background & Aims: There is a need to reduce the screen failure rate (SFR) in metabolic dysfunction-associated steatohepatitis (MASH) clinical trials (MASH+F2-3; MASH+F4) and identify people with high-risk MASH (MASH+F2-4) ...
Clinical and patient-reported outcomes in patients with chronic hepatitis B and C and non-alcoholic fatty liver disease from real-world practices in Saudi Arabia, Turkey and Egypt
(Wiley, 2024)
Patients with chronic liver disease (CLD) experience health-related quality of life (HRQoL) and patient-reported outcomes (PROs) impairments. We assessed and identified predictors of HRQoL and PROs in CLD patients from ...